Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)

Alain Hendlisz,E. Van Cutsem,Marc Peeters,Y. Humblet,Bart Neyns,A. Sobrero,G Devercelli,Michael S. Wolf,R Amado,S. Siena

Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)

2007

Alain Hendlisz
E. Van Cutsem
Marc Peeters
Y. Humblet
Bart Neyns
A. Sobrero
G Devercelli
Michael S. Wolf
R Amado
S. Siena

6560 Background: In a phase III study of mCRC pts, Pmab monotherapy significantly improved partial response (PR) rates and progression-free survival (PFS) compared with best supportive care (BSC). ...

Keywords:

Physical therapy
Patient-reported outcome
Colorectal cancer
Panitumumab
Intensive care medicine
Medicine
partial response
Internal medicine
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations